- Home
- XYL vs INSM Comparison
XYL vs INSM Comparison
Compare XYL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XYL | INSM |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5B | 35.2B |
| IPO Year | 2011 | 2000 |
Fundamental Metrics
Financial Performance| Metric | XYL | INSM |
|---|---|---|
| Price | $119.78 | $139.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 23 |
| Target Price | $157.89 | ★ $188.73 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 7.40 | N/A |
| EPS | ★ 3.92 | N/A |
| Revenue | ★ $9,035,000,000.00 | N/A |
| Revenue This Year | $2.88 | $168.46 |
| Revenue Next Year | $4.51 | $65.97 |
| P/E Ratio | $30.59 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $100.47 | $60.40 |
| 52 Week High | $154.27 | $212.75 |
Technical Indicators
Market Signals| Indicator | XYL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.48 | 35.86 |
| Support Level | N/A | $136.62 |
| Resistance Level | $131.80 | $167.01 |
| Average True Range (ATR) | 2.96 | 4.92 |
| MACD | -0.46 | -0.58 |
| Stochastic Oscillator | 8.15 | 12.58 |
Price Performance
Historical ComparisonAbout XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.